Vera Therapeutics announces atacicept Phase 3 data: 46% proteinuria reduction, 42% vs placebo (p<0.0001)

Vera Therapeutics, Inc.

Atacicept achieved 46% reduction from baseline in UPCR at week 36; 42% reduction vs placebo (p<0.0001).
Secondary endpoints: Gd-IgA1 reduced by 68%; hematuria resolved in 81% of participants with baseline hematuria.
Safety profile favorable: serious adverse events 0.5% (atacicept) vs 5% (placebo); no deaths in either group.
eGFR results not disclosed per FDA recommendation to sponsors of IgAN registrational trials.
Data presented at ASN Kidney Week and simultaneously published in The New England Journal of Medicine.

item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-25-268331
form_type: 8-K
ticker: VERA
cik: 0001831828
company_name: Vera Therapeutics, Inc.
filed_at: 2025-11-06T23:59:59+00:00
discovered_at: 2026-05-14T18:02:40.688033+00:00
generated_at: 2026-05-16T23:58:17.628918+00:00
sec_items: ["8.01", "9.01"]
event_type: other_material
sentiment: positive
materiality_score: 0.95
calibrated_materiality_score: 0.95
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-25-268331
json_url: https://secwatch.observer/filing/0001193125-25-268331.json
markdown_url: https://secwatch.observer/filing/0001193125-25-268331.md
text_url: https://secwatch.observer/filing/0001193125-25-268331.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1831828/000119312525268331/0001193125-25-268331-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1831828/000119312525268331/d30094d8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Comparable filings

QMCO

Quantum raises $100M equity, converts all convertible notes to equity; Q4 revenue above guidance

QUANTUM CORP /DE/ June 2, 2026, 10:41 AM ET other_material Items 1.01, 2.02, 2.03, 3.02, 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

CELC

Gedatolisib doubles PFS vs alpelisib in PIK3CA mutant HR+/HER2- ABC Phase 3 trial

Celcuity Inc. June 2, 2026, 8:10 AM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

IDYA

IDEAYA's darovasertib combo meets primary endpoint in Phase 2/3 OptimUM-02 trial for metastatic uveal melanoma

IDEAYA Biosciences, Inc. June 1, 2026, 4:05 PM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

FULC

Fulcrum Therapeutics discontinues pociredir program in SCD; initiates strategic review

Fulcrum Therapeutics, Inc. June 1, 2026, 4:05 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

USAR

USA Rare Earth selects South Carolina for $1.2B magnet facility; 490 jobs, 6,400 tpa capacity

USA Rare Earth, Inc. June 2, 2026, 9:14 AM ET other_material Items 1.01, 2.03, 7.01, 9.01

same SEC item: 9.01 same event type: other_material similar materiality

Filing page SEC filing

SHAK

Shake Shack cuts Q2 revenue guidance to $415-420M, same-shack sales to 2.5-3.0%

Shake Shack Inc. June 2, 2026, 8:06 AM ET other_material Items 7.01, 9.01

same SEC item: 9.01 same event type: other_material similar materiality

Filing page SEC filing

CWBHF

Charlotte's Web appoints BAT GC to board, closes debt conversion & US$10M investment

Charlotte's Web Holdings, Inc. June 1, 2026, 5:13 PM ET other_material Items 5.02, 5.07, 8.01

same SEC item: 8.01 same event type: other_material similar materiality

Filing page SEC filing

MDAI

Spectral AI gets FDA clearance for DeepView burn indication; targets first commercial sales by year-end 2026

Spectral AI, Inc. June 1, 2026, 4:01 PM ET other_material Items 5.07, 7.01, 9.01

same SEC item: 9.01 same event type: other_material similar materiality

Filing page SEC filing

Source: SEC EDGAR

accession 0001193125-25-268331

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.